Has Raymond Vivacqua received payments from drug or device companies?

Yes. Drug and device makers reported $9,254 in general payments to Raymond Vivacqua across 338 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raymond Vivacqua did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raymond Vivacqua come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raymond Vivacqua

Hematology & Oncology · Upland, PANPI 1821089350

Payments from drug & device makers

$9,254in general payments, 2019–2025

Across 338 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$1K
Johnson & Johnson$816
AstraZeneca$661
ASD Specialty Healthcare, LLC$533
E.r. Squibb & Sons, L.L.C.$454
Astellas Pharma US Inc$431
plus $5K from 51 others

$6,250in research payments, 2019–2025

Across 1 payment — averaging $6250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Celltrion, Inc.$6K

What the payments were for

Food & beverage$7,68991%
Education$7529%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	17	$1,363
Johnson & Johnson(2 entities)	38	$816
AstraZeneca(2 entities)	18	$661
ASD Specialty Healthcare, LLC	6	$533
E.r. Squibb & Sons, L.L.C.	23	$454
Astellas Pharma US Inc	14	$431
Amgen	15	$313
Genentech USA, Inc.	12	$304
Bristol Myers Squibb	10	$263
Sanofi	12	$254
Seagen Inc.	10	$245
Daiichi Sankyo Inc.	9	$228
Pharmacyclics LLC, An Abbvie Company	12	$213
EMD Serono, Inc.	3	$200
Verastem, Inc.	5	$196
Gilead(2 entities)	7	$194
Bayer	7	$194
Merck	12	$181
AbbVie	7	$174
Galvanize Therapeutics, Inc	1	$152
GSK	4	$145
Lilly USA, LLC	7	$134
Novartis	8	$130
Pfizer	8	$121
Teva Pharmaceuticals USA, Inc.	6	$87
Rigel Pharmaceuticals, Inc.	5	$79
Beigene USA, Inc.	1	$76
Tersera Therapeutics LLC	5	$74
Blueprint Medicines Corporation	4	$74
Kyowa Kirin, Inc.	4	$72
Boehringer Ingelheim	2	$59
Eisai Inc.	3	$59
Global Blood Therapeutics, Inc.	4	$58
Takeda Pharmaceuticals U.S.A., Inc.	3	$57
Karyopharm Therapeutics Inc.	3	$57
Dendreon Pharmaceuticals LLC	2	$53
Regeneron Healthcare Solutions, Inc.	2	$49
Pharmaessentia USA Corporation	2	$45
Taiho Oncology, Inc.	3	$43
Puma Biotechnology, Inc.	2	$39
Coherus Oncology, Inc.	2	$37
Sobi, Inc	2	$35
Mylan Institutional Inc.	2	$33
Lexicon Pharmaceuticals, Inc.	2	$30
Secura Bio, Inc.	2	$26
Jazz Pharmaceuticals Inc.	1	$25
Abbott	1	$24
Morphosys, US Inc.	1	$22
Genmab U.S., Inc.	1	$21
Stemline Therapeutics Inc.	1	$17
Ipsen Biopharmaceuticals, Inc	1	$17
Adaptive Biotechnologies Corporation	1	$16
AMAG Pharmaceuticals, Inc.	1	$15
Tesaro, Inc.	1	$14
EUSA Pharma (US) LLC	1	$14
Deciphera Pharmaceuticals Inc.	1	$14
Servier Pharmaceuticals LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,254 in reported general payments places this provider in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Other hematology & oncology in Upland

Diwakar DavarPittsburgh$21.6M
Jason LukePittsburgh$15M
Stephen BagleyPhiladelphia$13.1M
Leonard ApplemanPittsburgh$12.8M
Jing Zhou HouPittsburgh$11.9M
Taofeek OwonikokoPittsburgh$9.7M
Stephen SchusterPhiladelphia$9.5M
Pooja GhataliaPhiladelphia$8.3M
Corey LangerPhiladelphia$7.7M
Alfred GarfallPhiladelphia$7.6M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →